시장보고서
상품코드
1485013

항바이러스제 병용요법 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측, 유형별, 약물 조합별, 투여 경로별, 유통 채널별, 적응증별, 지역별, 경쟁사별(2019-2029년)

Antiviral Combination Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Drug Combination, By Route of Administration, By Distribution Channel, By Indications, By Region and Competition, 2019-2029F

발행일: | 리서치사: TechSci Research | 페이지 정보: 영문 184 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

항바이러스제 병용요법 세계 시장 규모는 2023년 491억 4,000만 달러로 평가되었고, 2029년까지 6.25%의 연평균 복합 성장률(CAGR)을 나타내며 예측 기간 동안 괄목할 만한 성장을 이룰 것으로 예상됩니다.

항바이러스제 병용요법 시장은 제약 및 헬스케어 산업에서 매우 중요한 부문으로 바이러스 감염증의 관리 및 치료에 중요한 역할을 하고 있습니다. 이 시장 보고서는 항바이러스제 병용요법 시장의 주요 구성 요소, 시장 성장 촉진요인 및 과제, 응용 분야, 경쟁 환경 등에 대한 종합적인 개요를 제공합니다. 항바이러스제 병용요법은 여러 가지 항바이러스제를 동시에 사용하여 바이러스 감염을 보다 효과적으로 퇴치하는 치료법입니다. 광범위한 바이러스에 대응하고 약제 내성 위험을 낮추며 치료 효과를 높일 수 있어 치료에서 중요한 위치를 차지하고 있습니다.

시장 개요
예측 기간 2025-2029년
시장 규모 : 2023년 491억 4,000만 달러
시장 규모 : 2029년 708억 6,000만 달러
CAGR : 2024-2029년 6.25%
급성장 부문 경구용
최대 시장 북미

항바이러스제 병용요법 시장은 다양한 요인에 의해 주도되고 있으며, 바이러스 감염과 싸우는 데 있어 중요한 요소로 작용하고 있습니다. HIV, B형 및 C형 간염, 독감, SARS-CoV-2(코로나19의 원인)와 같은 바이러스는 계속해서 전 세계 보건에 심각한 위협이 되고 있습니다. 새로운 바이러스의 출현과 기존 바이러스의 지속으로 인해 보다 효과적인 항바이러스 치료 요법의 개발 및 활용이 요구되고 있습니다. 이에 따라 의료진과 연구자들은 이러한 문제를 해결하기 위해 병용요법으로 눈을 돌리고 있습니다. 약제 내성 개발은 항바이러스제 병용요법 시장을 이끄는 또 다른 중요한 요인입니다. 바이러스는 시간이 지남에 따라 변이를 일으켜 단일 항바이러스제에 대한 내성을 획득하는 것으로 알려져 있습니다. 항바이러스제 병용요법은 바이러스의 수명 주기에서 여러 지점을 표적으로 삼아 내성 발생 가능성을 줄여 이 문제를 해결합니다. 이는 HIV나 간염과 같은 만성 바이러스 감염증을 관리할 때 특히 중요합니다. 항바이러스제 병용요법 시장은 항바이러스제 분야의 연구 개발 확대에 따른 수혜를 누리고 있습니다. 제약회사와 연구기관들은 새로운 항바이러스제의 발견과 개발, 기존 항바이러스제의 최적화를 위해 적극적으로 노력하고 있습니다. 이러한 발전은 바이러스 억제력을 개선하고 부작용을 줄이며 환자의 순응도를 향상시킬 수 있는 혁신적인 병용요법 요법을 개발할 수 있도록 돕고 있습니다.

효과적이고 편리한 치료에 대한 수요가 증가함에 따라 항바이러스제 병용요법의 채택이 증가하고 있습니다. 환자와 의료진은 우수한 바이러스 억제 효과를 제공하고 치료의 복잡성을 줄여줄 수 있는 치료법을 점점 더 많이 찾고 있습니다. 병용요법은 투여 요법이 간편하고 전반적인 치료 결과를 개선할 수 있다는 장점이 있어 바이러스 감염을 관리하는 데 있어 선호되는 선택이 되고 있습니다. 또한, 항바이러스제 개발의 발전은 항바이러스제 병용요법 시장에 큰 영향을 미치고 있습니다. 프로테아제 억제제, 중합효소 억제제, 엔트리 억제제 등 새로운 항바이러스제의 출현으로 보다 다양한 병용요법 접근법이 가능해졌습니다. 이러한 신약은 의료 서비스 제공업체에게 개별 환자의 필요에 따라 치료 요법을 조정할 수 있는 다양한 선택권을 제공합니다. 이 시장은 다수의 세계 및 지역 업체들이 경쟁적으로 참여하고 있습니다. 길리어드 사이언스, 글락소 스미스클라인, 애브비 등 대형 제약사들은 항바이러스제 병용요법 제조 및 판매에 적극적으로 나서고 있습니다. 이들 기업은 HIV, 간염, 독감 등 다양한 바이러스 감염증을 대상으로 다양한 병용요법 제품을 제공합니다.

항바이러스제 병용요법 시장은 큰 성장을 앞두고 있지만, 도전과제가 없는 것은 아닙니다. 특히 규제 당국이 안전성과 유효성을 보장하기 위해 노력하는 가운데, 병용요법 승인과 시장 진입에 있어 복잡한 규제가 걸림돌이 될 수 있습니다. 가격 압력은 특히 의료 예산이 제한된 지역에서 이러한 치료법의 경제성과 접근성에 영향을 미칠 수 있습니다. 병용요법의 복잡성은 환자 순응도 및 의료진 관리 측면에서 문제를 야기할 수 있습니다. 또한 약물 상호 작용과 부작용의 가능성을 면밀히 모니터링해야 합니다. 결론적으로, 항바이러스제 병용요법 시장은 바이러스 감염과 싸우는 데 있어 중요한 역할을 하고 있습니다. 유병률 증가, 약물 내성, 연구 개발 노력, 효과적인 치료법에 대한 수요, 약물의 발전이 시장을 주도하고 있으며, 앞으로도 성장세를 이어갈 것으로 예상됩니다. 새로운 항바이러스제 및 병용요법이 개발됨에 따라 시장은 바이러스 감염과 싸우는 사람들에게 더 많은 치료 옵션과 더 나은 치료 결과를 제공함으로써 의료 현장에서 그 중요성이 더욱 커질 것으로 보입니다.

주요 시장 성장 촉진요인

바이러스 감염증 증가

연구개발 확대

주요 시장 과제

약물 내성

부작용

규제의 복잡성

주요 시장 동향

맞춤형 치료

광범위한 스펙트럼의 약제

면역 조절의 통합

유전자 편집의 발전

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 항바이러스제 병용요법 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 유형별(브랜드, 제네릭)
    • 약제 병용별(DNA 폴리메라제 억제제, 역전사진 효소 억제제, 프로테아제 억제제, 노이라미니다제 억제제, 기타)
    • 투여 경로(경구, 정맥내)
    • 유통 채널별(병원 약국, 소매 약국, 기타 유통 채널)
    • 적응증별(인간 면역 결핍 바이러스, 간염, 기타)
    • 기업별(2023년)
    • 지역별
  • 시장 맵

제6장 북미의 항바이러스제 병용요법 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 유형별
    • 약제 병용별
    • 투여 경로별
    • 유통 채널별
    • 적응증별
    • 국가별
  • 북미 : 국가별 분석
    • 미국
    • 멕시코
    • 캐나다

제7장 유럽의 항바이러스제 병용요법 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 유형별
    • 약제 병용별
    • 투여 경로별
    • 유통 채널별
    • 적응증별
    • 국가별
  • 유럽 : 국가별 분석
    • 프랑스
    • 독일
    • 영국
    • 이탈리아
    • 스페인

제8장 아시아태평양의 항바이러스제 병용요법 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 유형별
    • 약제 병용별
    • 투여 경로별
    • 유통 채널별
    • 적응증별
    • 국가별
  • 아시아태평양 : 국가별 분석
    • 중국
    • 인도
    • 한국
    • 일본
    • 호주

제9장 남미의 항바이러스제 병용요법 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 유형별
    • 약제 병용별
    • 투여 경로별
    • 유통 채널별
    • 적응증별
    • 국가별
  • 남미 : 국가별 분석
    • 브라질
    • 아르헨티나
    • 콜롬비아

제10장 중동 및 아프리카의 항바이러스제 병용요법 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 유형별
    • 약제 병용별
    • 투여 경로별
    • 유통 채널별
    • 적응증별
    • 국가별
  • 중동 및 아프리카 : 국가별 분석
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트(UAE)

제11장 시장 역학

  • 성장 촉진요인
  • 과제

제12장 시장 동향과 발전

  • 합병 및 인수(해당하는 경우)
  • 제품 발매(있는 경우)
  • 최근 동향

제13장 Porter의 Five Forces 분석

  • 업계내 경쟁
  • 신규 참여 가능성
  • 공급업체의 힘
  • 고객의 힘
  • 대체품의 위협

제14장 경쟁 구도

  • Celltrion Inc.
  • GlaxoSmithKline plc
  • Gilead Sciences, Inc
  • AbbVie, Inc.
  • Bristol-Myers Squibb Company
  • Janssen Pharmaceuticals, Inc.
  • Cipla Limited
  • Viatris Inc
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd

제15장 전략적 제안

제16장 리서치사에 대해 & 면책사항

LSH 24.06.03

Global Antiviral Combination Therapy Market was valued at USD 49.14 Billion in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 6.25% through 2029. The Antiviral Combination Therapy Market is a pivotal segment within the pharmaceutical and healthcare industries, playing a crucial role in the management and treatment of viral infections. This market description provides a comprehensive overview of the Antiviral Combination Therapy Market, highlighting its key components, drivers, challenges, applications, and competitive landscape. Antiviral combination therapy involves the simultaneous use of multiple antiviral drugs to combat viral infections more effectively. It has gained substantial importance in the treatment landscape due to its ability to address a broad spectrum of viruses, reduce the risk of drug resistance, and enhance treatment outcomes.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 49.14 Billion
Market Size 2029USD 70.86 Billion
CAGR 2024-20296.25%
Fastest Growing SegmentOral
Largest MarketNorth America

The Antiviral Combination Therapy Market is driven by a multitude of factors, making it a critical element in the fight against viral infections. One of the primary drivers of this market is the increasing prevalence of viral infections worldwide. Viruses, such as HIV, hepatitis B and C, influenza, and SARS-CoV-2 (responsible for COVID-19), continue to pose significant global health threats. The ongoing emergence of new viral strains and the persistence of established viruses necessitate the development and utilization of more effective antiviral treatment regimens. As a result, healthcare providers and researchers are turning to combination therapy to combat these challenges. The development of drug resistance is another critical factor propelling the Antiviral Combination Therapy Market. Viruses are known to mutate and develop resistance to single antiviral drugs over time. Antiviral combination therapy addresses this issue by targeting multiple points in the virus's life cycle, reducing the likelihood of resistance development. This is particularly crucial in the management of chronic viral infections like HIV and hepatitis. The Antiviral Combination Therapy Market benefits from expanding research and development efforts in the field of antiviral drugs. Pharmaceutical companies and research institutions are actively engaged in discovering and developing new antiviral agents and optimizing existing ones. These advancements lead to the creation of innovative combination therapy regimens that offer improved viral suppression, fewer side effects, and enhanced patient adherence.

Growing demand for effective and convenient treatments drives the adoption of antiviral combination therapy. Patients and healthcare providers are increasingly seeking therapies that provide superior viral suppression and reduce treatment complexity. Combination therapy offers the advantage of simpler dosing regimens and improved overall outcomes, making it a preferred choice for managing viral infections. Furthermore, advancements in antiviral drug development have a significant impact on the Antiviral Combination Therapy Market. The emergence of novel antiviral agents, including protease inhibitors, polymerase inhibitors, and entry inhibitors, allows for the creation of more diversified combination therapy approaches. These newer drugs provide healthcare providers with a broader range of options to tailor treatment regimens to individual patient needs. The Antiviral Combination Therapy Market presents a competitive landscape with numerous global and regional players. Major pharmaceutical companies like Gilead Sciences, GlaxoSmithKline, and AbbVie are actively involved in the production and distribution of antiviral combination therapies. These companies offer a range of combination therapy products targeting various viral infections, including HIV, hepatitis, and influenza.

While the Antiviral Combination Therapy Market is poised for significant growth, it is not without its challenges. Regulatory complexities in the approval and market access of combination therapies can be a hindrance, particularly as regulatory bodies strive to ensure safety and efficacy. Pricing pressures, especially in regions with limited healthcare budgets, can affect the affordability and accessibility of these therapies. The complexity of combination therapy regimens can pose challenges in terms of patient adherence and healthcare provider management. Furthermore, the potential for drug interactions and side effects needs to be carefully monitored. In conclusion, the Antiviral Combination Therapy Market plays a crucial role in the fight against viral infections. With increasing prevalence, drug resistance, research and development efforts, demand for effective treatments, and drug advancements driving the market, it is expected to continue its growth trajectory. As new antiviral agents and combination regimens are developed, the market will offer improved treatment options and outcomes for individuals battling viral infections, reinforcing its significance in the healthcare landscape.

Key Market Drivers

Increasing prevalence of viral infections

The Antiviral Combination Therapy Market is experiencing significant growth due to the increasing prevalence of viral infections worldwide. Viruses represent a diverse group of pathogens that have a profound impact on global public health. With viruses like HIV, hepatitis B and C, influenza, and, most recently, SARS-CoV-2 responsible for COVID-19, viral infections continue to pose substantial health threats. One of the primary drivers for the market's expansion is the persistent emergence of new viral strains and the continued circulation of established viruses. These infectious agents have proven their ability to adapt, mutate, and develop resistance to antiviral treatments over time. As a result, it has become increasingly challenging to manage and control viral infections using traditional single-agent antiviral therapies. Antiviral combination therapy has emerged as a powerful strategy to address this growing challenge. By using multiple antiviral drugs concurrently, this approach targets different stages of the viral life cycle or multiple viral proteins simultaneously. This multi-pronged attack significantly reduces the risk of drug resistance development, making it an effective option for the management of viral infections. The rise of antiviral combination therapy can be most prominently observed in the treatment of HIV. HIV's ability to develop resistance to single antiretroviral drugs led to the introduction of highly active antiretroviral therapy (HAART), which combines several antiretroviral agents. This approach has transformed HIV from a life-threatening disease to a manageable chronic condition.

The increasing prevalence of viral infections, coupled with the persistence of established viruses and the emergence of novel ones, has stimulated the development of innovative antiviral combination regimens. Researchers and pharmaceutical companies are actively exploring new drug combinations to improve viral suppression, reduce side effects, and enhance patient adherence. This research and development drive is a significant contributor to the growth of the Antiviral Combination Therapy Market. Moreover, the ongoing COVID-19 pandemic has highlighted the importance of antiviral therapies. With the rapid development of vaccines and antiviral drugs targeting SARS-CoV-2, the world witnessed the power of combination therapies in effectively combating a novel viral pathogen. This experience is expected to drive further interest and investment in antiviral combination therapy development and adoption in the future. In conclusion, the increasing prevalence of viral infections and the challenges posed by drug resistance have led to the growing adoption of antiviral combination therapy. This approach offers a multifaceted solution to the complex issue of viral infections, making it a vital component in the healthcare industry's arsenal against these evolving and sometimes elusive pathogens. As the global health landscape continues to be shaped by viral threats, antiviral combination therapy is poised to play a pivotal role in safeguarding public health.

Expanding research and development efforts

The Antiviral Combination Therapy Market is being driven by the expanding research and development efforts aimed at tackling a broad spectrum of viral infections. The relentless pursuit of innovative antiviral treatments and regimens to combat these infectious agents has become a key driver for the market's growth.

Viruses are known for their ability to adapt, mutate, and develop resistance to single antiviral drugs, making it challenging to develop effective treatments. In response, research and development (R&D) efforts have intensified to create new antiviral agents and optimize existing ones. The development of innovative antiviral drugs has paved the way for more diversified and powerful combination therapy regimens, allowing for enhanced viral suppression and improved treatment outcomes. One of the most notable areas of research has been the development of antiviral agents that target different stages of the viral life cycle or multiple viral proteins simultaneously. These multifaceted therapies significantly reduce the risk of drug resistance development and offer a more comprehensive approach to viral infections. For example, protease inhibitors, polymerase inhibitors, entry inhibitors, and other innovative drug classes have been introduced to bolster the antiviral arsenal. The persistent threat of viral infections and the need for more effective treatments have driven research initiatives to explore novel drug combinations. This includes investigating the potential synergistic effects of different antiviral agents, assessing their safety and efficacy, and optimizing dosing regimens. The goal is to create combination therapies that maximize viral suppression while minimizing side effects and drug interactions. The ongoing COVID-19 pandemic has further accelerated R&D efforts in the antiviral field. Researchers and pharmaceutical companies worldwide have mobilized to develop antiviral drugs and combination therapies targeting the SARS-CoV-2 virus. The rapid development of treatments and vaccines for COVID-19 has underscored the significance of antiviral combination therapy in addressing emerging viral threats.

Moreover, the scientific community is continuously working to enhance our understanding of viral infections, their mechanisms, and their interaction with the human immune system. This knowledge drives the development of more precise and effective antiviral treatments. The expansion of R&D efforts in the antiviral field is not limited to traditional pharmaceutical companies but also includes academic institutions, research organizations, and biotechnology firms. In summary, the Antiviral Combination Therapy Market benefits from the expanding research and development efforts dedicated to combatting viral infections. These efforts encompass the development of new antiviral agents, the optimization of existing drugs, and the exploration of innovative combination therapy regimens. As the global health landscape continues to be shaped by viral threats, the ongoing commitment to research and development is expected to yield more effective antiviral treatments and further drive the market's growth.

Key Market Challenges

Drug resistance

Drug resistance is a significant challenge in the Antiviral Combination Therapy Market as it hampers the effectiveness of treatment for viral infections. When multiple antiviral drugs are used in combination, the risk of resistance development is reduced compared to monotherapy. However, the emergence of resistant viral strains remains a concern, especially in long-term treatment. These resistant strains can render the antiviral combination therapy ineffective, limiting treatment options and potentially leading to treatment failure. This challenge underscores the need for continuous research and development of new antiviral drugs and innovative treatment strategies to stay ahead of evolving viral resistance and ensure the long-term efficacy of combination therapies.

Adverse effects

Adverse effects pose a significant challenge in the Antiviral Combination Therapy Market as they can impact patient compliance and overall treatment outcomes. Combining multiple antiviral drugs increases the risk of side effects and drug interactions, potentially leading to tolerability issues and treatment discontinuation. Additionally, some antiviral medications may have long-term consequences, such as organ toxicity or drug resistance. Managing and minimizing these adverse effects is crucial to ensure patient adherence and the success of combination therapies. Balancing the benefits of viral suppression with the potential harm from side effects requires constant monitoring and the development of safer and more tolerable antiviral combinations to improve patient quality of life and treatment outcomes.

Regulatory complexities

Regulatory complexities present a formidable challenge in the Antiviral Combination Therapy Market. Developing and gaining approval for combination therapies involves navigating intricate regulatory pathways, often requiring extensive clinical trials and stringent safety and efficacy evaluations. These complexities can significantly delay time-to-market, increasing development costs and limiting patient access to innovative therapies. Moreover, harmonizing regulatory standards across different regions and addressing evolving guidelines further complicates the process. As the antiviral landscape evolves rapidly, regulatory challenges must be met with agility and collaboration among stakeholders to ensure that safe and effective combination therapies can be efficiently brought to market, benefiting patients worldwide.

Key Market Trends

Personalized Therapies

Personalized therapies are an emerging trend in the Antiviral Combination Therapy Market, driven by the growing recognition of individual variations in patient response to antiviral treatments. Tailoring combination regimens to the specific genetic, immunological, and virological characteristics of each patient enhances treatment efficacy while minimizing side effects. Advances in genomics and diagnostic tools enable healthcare providers to identify optimal drug combinations, dosages, and treatment durations for a more precise approach. This trend reflects a shift towards more patient-centric care, with the potential to improve outcomes and reduce the development of drug resistance, marking a significant evolution in the management of viral infections.

Broad-Spectrum Agents

Broad-spectrum agents represent a notable trend in the Antiviral Combination Therapy Market, driven by the need for versatile antiviral treatments. These agents are designed to target multiple viral strains or even different types of viruses, reducing the complexity of treatment regimens. By developing combination therapies that incorporate broad-spectrum antivirals, healthcare providers can effectively combat a range of viral infections with fewer drugs. This trend not only simplifies treatment but also provides an important response to emerging and mutating viral threats, offering a more versatile and efficient approach to antiviral therapy that can adapt to the evolving landscape of infectious diseases.

Immunomodulation Integration

Immunomodulation integration is a noteworthy trend in the Antiviral Combination Therapy Market, involving the combination of antiviral drugs with immunomodulatory agents. This approach harnesses the patient's immune system to enhance antiviral effectiveness. By combining antivirals with immunomodulators, healthcare providers can create a synergistic response, boosting the body's ability to combat viral infections. This trend not only improves treatment outcomes but also minimizes the risk of drug resistance. As our understanding of immunology advances, the integration of immunomodulation into combination therapies holds great promise for more robust and holistic antiviral treatments, ultimately enhancing patient care and broadening the arsenal against viral diseases.

Gene Editing Advancements

Gene editing advancements represent a cutting-edge trend in the Antiviral Combination Therapy Market, where innovative technologies like CRISPR are being explored to directly target and modify viral genetic material. By integrating gene editing techniques into combination therapies, researchers aim to develop highly specific and potent antiviral strategies. This trend holds significant potential for eradicating persistent viral infections, reducing the need for long-term treatment, and potentially achieving functional cures. While in the early stages, these advancements are a testament to the ever-evolving landscape of antiviral therapies, offering the prospect of more precise and enduring solutions for a range of viral diseases.

Segmental Insights

Route of Administration Insights

Oral administration is a dominant route of delivery in the Antiviral Combination Therapy Market due to its convenience, patient compliance, and wide acceptance. Oral antiviral medications are favored for their ease of use, obviating the need for invasive procedures or healthcare facility visits. They offer patients the flexibility to manage their treatment at home, promoting adherence to therapy regimens. This accessibility has been especially crucial in viral pandemics, such as COVID-19, where quick distribution and patient self-administration are paramount. The dominance of oral antiviral combination therapies reflects the preference for user-friendly and efficient treatment options in managing a range of viral infections.

Regional Insights

North America is dominant in the Antiviral Combination Therapy Market. The region boasts pharmaceutical industry, extensive research infrastructure, and a favorable regulatory environment, which fosters innovation and expedites drug development. Also, North America's healthcare systems are well-equipped to adopt and promote advanced therapies, including antiviral combinations. Moreover, the high prevalence of viral infections, such as HIV and hepatitis, and the substantial healthcare expenditure in the region drive the demand for effective antiviral treatments. The availability of well-established healthcare reimbursement systems and a sophisticated market for pharmaceuticals further solidify North America's leadership in this market.

Key Market Players

Celltrion Inc.

GlaxoSmithKline plc

Gilead Sciences, Inc

AbbVie, Inc.

Bristol-Myers Squibb Company

Janssen Pharmaceuticals, Inc.

Cipla Limited

Viatris Inc

Merck & Co., Inc.

F. Hoffmann-La Roche Ltd

Report Scope:

In this report, the Global Antiviral Combination Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antiviral Combination Therapy Market, By Type:

    Branded Generic

Antiviral Combination Therapy Market, By Drug Combination:

    DNA Polymerase Inhibitors Reverse Transcriptase Inhibitors Protease Inhibitors Neuraminidase Inhibitors Others

Antiviral Combination Therapy Market, By Route of Administration:

    Oral Intravenous

Antiviral Combination Therapy Market, By Distribution Channel:

    Hospital Pharmacies Retail Pharmacies Others

Antiviral Combination Therapy Market, By Indications:

    Human Immunodeficiency Virus Hepatitis Others

Antiviral Combination Therapy Market, By Region:

    North America

United States

Canada

Mexico

    Europe

France

United Kingdom

Italy

Germany

Spain

    Asia-Pacific

China

India

Japan

Australia

South Korea

    South America

Brazil

Argentina

Colombia

    Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Antiviral Combination Therapy Market.

Available Customizations:

Global Antiviral Combination Therapy market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Antiviral Combination Therapy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Branded, Generic)
    • 5.2.2. By Drug Combination (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Others)
    • 5.2.3. By Route of Administration (Oral, Intravenous)
    • 5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels)
    • 5.2.5. By Indication (Human Immunodeficiency Virus, Hepatitis, Others)
    • 5.2.6. By Company (2023)
    • 5.2.7. By Region
  • 5.3. Market Map

6. North America Antiviral Combination Therapy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Drug Combination
    • 6.2.3. By Route of Administration
    • 6.2.4. By Distribution Channel
    • 6.2.5. By Indication
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Antiviral Combination Therapy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. Drug Combination
        • 6.3.1.2.3. Route of Administration
        • 6.3.1.2.4. By Distribution Channel
        • 6.3.1.2.5. By Indication
    • 6.3.2. Mexico Antiviral Combination Therapy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Drug Combination
        • 6.3.2.2.3. By Route of Administration
        • 6.3.2.2.4. By Distribution Channel
        • 6.3.2.2.5. By Indication
    • 6.3.3. Canada Antiviral Combination Therapy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Drug Combination
        • 6.3.3.2.3. By Route of Administration
        • 6.3.3.2.4. By Distribution Channel
        • 6.3.3.2.5. By Indication

7. Europe Antiviral Combination Therapy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Drug Combination
    • 7.2.3. By Route of Administration
    • 7.2.4. By Distribution Channel
    • 7.2.5. By Indication
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Antiviral Combination Therapy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Drug Combination
        • 7.3.1.2.3. By Route of Administration
        • 7.3.1.2.4. By Distribution Channel
        • 7.3.1.2.5. By Indication
    • 7.3.2. Germany Antiviral Combination Therapy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Drug Combination
        • 7.3.2.2.3. By Route of Administration
        • 7.3.2.2.4. By Distribution Channel
        • 7.3.2.2.5. By Indication
    • 7.3.3. United Kingdom Antiviral Combination Therapy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Drug Combination
        • 7.3.3.2.3. By Route of Administration
        • 7.3.3.2.4. By Distribution Channel
        • 7.3.3.2.5. By Indication
    • 7.3.4. Italy Antiviral Combination Therapy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Drug Combination
        • 7.3.4.2.3. By Route of Administration
        • 7.3.4.2.4. By Distribution Channel
        • 7.3.4.2.5. By Indication
    • 7.3.5. Spain Antiviral Combination Therapy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Drug Combination
        • 7.3.5.2.3. By Route of Administration
        • 7.3.5.2.4. By Distribution Channel
        • 7.3.5.2.5. By Indication

8. Asia-Pacific Antiviral Combination Therapy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Drug Combination
    • 8.2.3. By Route of Administration
    • 8.2.4. By Distribution Channel
    • 8.2.5. By Indication
    • 8.2.6. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Antiviral Combination Therapy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Drug Combination
        • 8.3.1.2.3. By Route of Administration
        • 8.3.1.2.4. By Distribution Channel
        • 8.3.1.2.5. By Indication
    • 8.3.2. India Antiviral Combination Therapy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Drug Combination
        • 8.3.2.2.3. By Route of Administration
        • 8.3.2.2.4. By Distribution Channel
        • 8.3.2.2.5. By Indication
    • 8.3.3. South Korea Antiviral Combination Therapy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Drug Combination
        • 8.3.3.2.3. By Route of Administration
        • 8.3.3.2.4. By Distribution Channel
        • 8.3.3.2.5. By Indication
    • 8.3.4. Japan Antiviral Combination Therapy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Drug Combination
        • 8.3.4.2.3. By Route of Administration
        • 8.3.4.2.4. By Distribution Channel
        • 8.3.4.2.5. By Indication
    • 8.3.5. Australia Antiviral Combination Therapy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Drug Combination
        • 8.3.5.2.3. By Route of Administration
        • 8.3.5.2.4. By Distribution Channel
        • 8.3.5.2.5. By Indication

9. South America Antiviral Combination Therapy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Drug Combination
    • 9.2.3. By Route of Administration
    • 9.2.4. By Distribution Channel
    • 9.2.5. By Indication
    • 9.2.6. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Antiviral Combination Therapy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Drug Combination
        • 9.3.1.2.3. By Route of Administration
        • 9.3.1.2.4. By Distribution Channel
        • 9.3.1.2.5. By Indication
    • 9.3.2. Argentina Antiviral Combination Therapy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Drug Combination
        • 9.3.2.2.3. By Route of Administration
        • 9.3.2.2.4. By Distribution Channel
        • 9.3.2.2.5. By Indication
    • 9.3.3. Colombia Antiviral Combination Therapy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Drug Combination
        • 9.3.3.2.3. By Route of Administration
        • 9.3.3.2.4. By Distribution Channel
        • 9.3.3.2.5. By Indication

10. Middle East and Africa Antiviral Combination Therapy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Drug Combination
    • 10.2.3. By Route of Administration
    • 10.2.4. By Distribution Channel
    • 10.2.5. By Indication
    • 10.2.6. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Antiviral Combination Therapy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Drug Combination
        • 10.3.1.2.3. By Route of Administration
        • 10.3.1.2.4. By Distribution Channel
        • 10.3.1.2.5. By Indication
    • 10.3.2. Saudi Arabia Antiviral Combination Therapy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Drug Combination
        • 10.3.2.2.3. By Route of Administration
        • 10.3.2.2.4. By Distribution Channel
        • 10.3.2.2.5. By Indication
    • 10.3.3. UAE Antiviral Combination Therapy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Drug Combination
        • 10.3.3.2.3. By Route of Administration
        • 10.3.3.2.4. By Distribution Channel
        • 10.3.3.2.5. By Indication

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porters Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Celltrion Inc.
    • 14.1.1. Business Overview
    • 14.1.2. Product & Service Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Financials (If Listed)
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. GlaxoSmithKline plc
  • 14.3. Gilead Sciences, Inc
  • 14.4. AbbVie, Inc.
  • 14.5. Bristol-Myers Squibb Company
  • 14.6. Janssen Pharmaceuticals, Inc.
  • 14.7. Cipla Limited
  • 14.8. Viatris Inc
  • 14.9. Merck & Co., Inc.
  • 14.10. F. Hoffmann-La Roche Ltd

15. Strategic Recommendations

16. About Us & Disclaimer

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제